Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Probiotic for the Prevention of Functional Disorders in Childhood

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by University of Bari.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Ruggiero Francavilla, University of Bari Identifier:
First received: August 16, 2012
Last updated: August 20, 2012
Last verified: August 2012

The present study has several aims:

  1. Establish whether Lactobacillus Rhamnosus Strain GG is able to prevent the onset of IBS in a high risk group of children enrolled after an acute gastroenteritis (the study has been powered to this aim).
  2. Establish whether Lactobacillus Rhamnosus Strain GG is able to stabilize the intestinal microbiota after an acute gastroenteritis.
  3. Define the intestinal microbiota of children following an acute gastroenteritis and identify, if possible, a modification of the microbiota that can predict the emergence of Irritable Bowel Syndrome.

Condition Intervention
Other: Lactobacillus Rhamnosus Strain GG

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized Controlled Trial of Lactobacillus Rhamnosus Strain GG for The Prevention of Functional Abdominal Pain Children After Acute Gastroenteritis

Resource links provided by NLM:

Further study details as provided by University of Bari:

Primary Outcome Measures:
  • Prevention of Abdominal pain [ Time Frame: 18 months ]

    Primary outcome will be the incidence in IBS in children receiving LGG as compared to those receiving placebo. We have chosen pain as the primary outcome measure, in line with the proposed points-toconsider for IBS trials (Corazziari E. Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmcol Ther 2003;18:569).

    IBS or chronic abdominal pain will be diagnosed and categorised according to ROME III criteria (Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130).

Secondary Outcome Measures:
  • Incidence of IBS [ Time Frame: 6 months ]
    Evaluation of frequency/severity of symptoms according to treatment arm;

  • Children's health [ Time Frame: 24 months ]
    Evaluation of perception of children's health according to parents

  • Intestinal microbiota [ Time Frame: 24 months ]
    Investigate the modification of intestinal microbiota.

Estimated Enrollment: 400
Study Start Date: September 2012
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lactobacillus Rhamnosus Strain GG
LGG (6 × 109 colony forming units)
Other: Lactobacillus Rhamnosus Strain GG
Lactobacillus Rhamnosus Strain GG
Other Name: LGG
Placebo Comparator: Placebo
Other: Lactobacillus Rhamnosus Strain GG
Lactobacillus Rhamnosus Strain GG
Other Name: LGG

  Show Detailed Description


Ages Eligible for Study:   3 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Children of 3 - 16 years of age;
  2. Either sex.

Exclusion Criteria:

  1. Chronic disease,
  2. Clinical history of abdominal pain history suggestive for functional dyspepsia/aerophagia/abdominal migraine
  3. Growth failure,
  4. Alarm signs of organic conditions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01671137

Contact: Ruggiero Francavilla 0805592963

Clinica Pediatrica Active, not recruiting
Bari, Puglia, Italy, 70125
Sponsors and Collaborators
University of Bari
Principal Investigator: Ruggiero Francavilla University of Bari
  More Information

Responsible Party: Ruggiero Francavilla, MD, PhD, University of Bari Identifier: NCT01671137     History of Changes
Other Study ID Numbers: PrevenDAR
Prevent-001 ( Other Grant/Funding Number: Uniba001 )
Study First Received: August 16, 2012
Last Updated: August 20, 2012

Keywords provided by University of Bari:
Lactobacillus GG
Functional Abdominal Pain

Additional relevant MeSH terms:
Abdominal Pain
Gastrointestinal Diseases
Digestive System Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive processed this record on April 27, 2017